Ultrafiltration through hollow fibrous filters followed by purification in interrupted and linear urografin gradients yielded a Lassa virus suspension of high concentration. The use of gamma-irradiation for inactivation of the frozen virus suspension (-70 degrees C) caused no apparent structural changes of virions and made it possible to examine Lassa virus in electron microscope by negative staining. The observed virus particles in their morphology and sizes did not differ from previously described particles of other members of the Arenaviridae family. In ultrathin sections of Lassa virus-infected Vero cells, atypical virions were sometimes visible alongside with typical particles. Within one type of such particles no ribosome-like granules could be detected. Such "hollow" particles may possibly be defective virions. Another kind of atypical particles contained homogeneous electron-dense core and resembled mycoplasma. Of greatest interest are the particles with heterogeneous core in which "sandy" granules can be distinguished. The presence of greater amounts of uranophilic material than usually may be explained by getting into the virion in the process of its formation of a greater amount of genetic material than that present in typical virions.

Download full-text PDF

Source

Publication Analysis

Top Keywords

lassa virus
8
virus suspension
8
particles
7
[electron microscopic
4
microscopic study
4
lassa
4
study lassa
4
lassa virus]
4
virus] ultrafiltration
4
ultrafiltration hollow
4

Similar Publications

The SARS-CoV-2 pandemic has highlighted the need for society, as a whole, to be prepared against potential pandemics caused by a variety of different viral families of concern. Here, we describe a roadmap towards the identification and validation of conserved T cell epitope regions from Viral Families of Pandemic Potential (VFPP). For each viral family, we select a prototype virus, the sequence of which could be utilized in epitope identification screens.

View Article and Find Full Text PDF

Current perspectives on vaccines and therapeutics for Lassa Fever.

Virol J

December 2024

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.

View Article and Find Full Text PDF

Systematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.

Am J Trop Med Hyg

December 2024

Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.

Article Synopsis
  • The systematic review focuses on reproductive health issues faced by female survivors of Lassa fever and Ebola virus disease.
  • Thirteen studies reviewed predominantly highlight negative outcomes related to reproductive health among EVD survivors, including menstrual irregularities and pregnancy loss, with no research identified on LF survivors.
  • The analysis indicates that about 14% of female EVD survivors experience adverse reproductive health outcomes, revealing a significant need for further research in this area.
View Article and Find Full Text PDF

U-73122, a phospholipase C inhibitor, impairs lymphocytic choriomeningitis virus virion infectivity.

J Gen Virol

December 2024

Laboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Lassa virus (LASV) is an Old World (OW) mammarenavirus that causes Lassa fever, a life-threatening acute febrile disease endemic in West Africa. Lymphocytic choriomeningitis virus (LCMV) is a worldwide-distributed, prototypic OW mammarenavirus of clinical significance that has been largely neglected as a human pathogen. No licensed OW mammarenavirus vaccines are available, and the current therapeutic option is limited to the off-label use of ribavirin, which offers only partial efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!